RxDoctor Payments Data

Micah Jacobs, MD

Infectious Disease · Pittsburgh, PANPI 1386845022

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $167,327 of the $205,641 with a category attached, or 81.4%. AbbVie accounts for 67.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $66,126 and has fallen 88.6% since, to $7,558 in 2025. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$205,641in general payments, 2019–2025

Across 662 payments — averaging $310.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$139K
  • Cumberland Pharmaceuticals, Inc.$44K
  • Paratek Pharmaceuticals, Inc.$6K
  • Merck$6K
  • Insmed, Inc.$5K
  • Invivyd Inc$3K
  • plus $2K from 15 others
$30,874in research payments, 2019–2025

Across 6 payments — averaging $5145.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$25K
  • Ferring Pharmaceuticals AS$6K

What the payments were for

  • Consulting fees$9,2995%
  • Speaking & faculty fees$167,32781%
  • Travel & lodging$17,0038%
  • Food & beverage$11,4886%
  • Education$5240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,641 in reported general payments places this provider in the 95th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$278,308
Medicare patients
294
Services billed
22,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod14$2,708
CeftriaxoneCeftriaxone Sodium36$2,356
Cephalexin81$1,636
Clarithromycin25$1,325
Doxycycline Hyclate58$1,287
Ethambutol Hcl21$1,282
Cefazolin Sodium17$935
Rifampin28$901
Azithromycin18$306
Fluconazole14$285
Doxycycline Monohydrate12$238
Ciprofloxacin Hcl18$170
Amoxicillin40$168
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$130

Paid to pharmacies, not to this prescriber.

Other infectious disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →